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ranscatheter aortic valve replacement (TAVR) has rapidly emerged as the treatment of choice in inoperable patients and a reasonable alternative to surgical aortic valve replacement in patients at high and intermediate surgical risk. 1 The success of this technology is in large part because of the rigor with which quantitative echocardiography by core laboratories has been used to assess native and prosthetic aortic valve function. The initial PARTNER I trial (Placement of Aortic Transcatheter Valves) was a model for echo core laboratory best practices, and serial measurements using consistent methodology have led to reassurances of transcatheter heart valve (THV) durability. 2 In addition, because of the meticulousness with which echocardiographic core labs record and maintain their data, one of the early concerns of TAVR, inconsistent reporting of the incidence and prognostic significance of paravalvular regurgitation (PVR), could be rigorously investigated. The investigation became the basis for a new proposed grading scheme, 3 which has led to studies that clarify the role of PVR on TAVR outcomes. 4 As new transcatheter valves are developed to address the shortcomings of current iterations of THV, differences in procedural and hemodynamic success may allow clinicians to make decisions about valve choice for their patients. One of the first trials comparing different THV devices was the CHOICE trial (Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus Edwards SAPIEN XT). 5 It is important to note that echocardiographic results were not core laboratory-assessed but site-reported, raising questions about the validity of the comparison. In fact, the incidence of moderate/severe PVR by echocardiography did not correlate with either angiography or cardiac magnetic resonance imaging for the CoreValve (while correlating relatively well for the balloon-expandable valve). Nonetheless, this trial reported greater PVR with the self-expanding valve compared with the balloon-expandable valve, a finding supported by earlier meta-analyses. 6 However, subsequent iterations of both valves have shown significantly less PVR. 7, 8 In fact, a 60-patient, multicenter trial of the newest iteration of a commercially available self-expanding valve, the Evolut PRO (Medtronic), was recently shown to have only 1 patient with moderate PVR after implantation. 9 To achieve these results, pre-TAVR balloon aortic valvuloplasty was performed in 51.7% of patients, and postdilation of the valve was performed in 26.7% of patients. In addition, 35% of patients required either resheathing or recapturing of the valve.
Another complication of TAVR has been the high incidence of new permanent pacemakers (PPM). For the newest iteration of the balloon-expandable valve, the PPM rate was 12%. 9 Outcomes after PPM and TAVR have been mixed. One study suggested that 30-day PPM was a protective factor for the occurrence of unexpected (sudden or unknown) death and was not associated with any increase in overall or cardiovascular death or rehospitalization for heart failure after a mean follow-up of ≈2 years. 10 The PARTNER trial, in contrast, found that new PPM was associated with a longer duration of hospitalization and higher rates of repeat hospitalization and mortality or repeat hospitalization alone at 1 year.
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A new mechanically expanded THV was designed to address a number of issues with prior THV designs. With mechanical expansion and retraction, the valve is designed to be fully recapturable after positioning, ensuring that final release only occurs when optimal positioning to reduce PVR has been achieved. The valve design allows for this to be achieved under a controlled and hemodynamically stable condition. The novel polycarbonate-based urethane adaptive seal skirt design further allows for reducing PVR by filling in irregular gaps between stent frame and native anatomy. Last, the metal frame has to be maximally foreshortened for the locking mechanism to engage, and thus the maximum and likely more consistent hemodynamics can, in theory, occur with every implant. Unfortunately, the obligatory full expansion of the valve led to increased pressure on the membranous septum, resulting in higher PPM rates. An early study comparing procedural outcomes of the Lotus Valve (Boston Scientific) and the Core Valve Classic (Medtronic) using core laboratoryassessed outcomes 12 showed greater device success, driven by higher rates of correct anatomic positioning and lower rates of PVR for the mechanically expanding Lotus Valve. The Nordic Lotus-TAVR Registry similarly showed extremely low rates of PVR (1 of 154 patients with moderate PVR) but a 28% pacemaker rate with this valve. 13 The REPRISE II trial (Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System-Randomized Clinical Evaluation) results were recently reported.
14 Investigators compared the outcomes of this first prospective, multicenter, randomized controlled trial of the Lotus Valve and the Core Valve (CoreValve Classic or Evolut R) in high-risk patients with severe aortic stenosis using a noninferiority design. The Lotus Valve met noninferiority criteria for the primary safety composite end point at 30 days (20.3% for Lotus and 17.2% for Core Valve, P=0.003 for noninferiority) and the primary effectiveness end point at 1 year (15.4% versus 25.5%, P<0.001). The superiority analysis for primary effectiveness was also statistically significant (P<0.001), as was 1-year moderate or severe PVR (0.9% versus 6.8%, P<0.001). The Lotus Valve did have significantly higher rates of new PPM (35.5% versus 19.6%, P<0.001) and valve thrombosis (1.5% versus 0%).
In this issue of Circulation, the Asch et al 15 study is a comprehensive report of the echocardiographic findings of the REPRISE III trial and the impact of hemodynamic results on clinical outcomes. On the 912 patients randomized, 874 patients received the intended valve. Of these, the following had discharge or 30-day evaluable parameters for THV function: 766 had a mean gradient, 733 had a Doppler velocity index, and 639 had an aortic valve area (AVA). Thus, ~27% of patients (26% in the Lotus group and 30% in the Core Valve group) did not have a calculated AVA. It is important to note that the mean gradient, AVA, and Doppler velocity index were all consistent with less optimal results with the Lotus Valve, despite similar left ventricular outflow diameters and aortic annular dimensions. This finding is not surprising, however, because in other nonrandomized studies, the supra-annular Core Valve has consistently shown larger valve areas or lower mean gradients compared with annular devices. 16 What is unexpected is the 8.6% (n = 48) of patients in the Lotus group (compared with 1.2% of the Core Valve patients) who qualified as having mild stenosis at 30 days. Despite this suboptimal hemodynamic result, there seemed to be no shortterm difference in outcomes in the group as a whole or for each valve type, although more valve thrombosis was seen with the Lotus Valve. The authors did not report the prevalence of prosthesis-patient mismatch that has been shown to affect long-term outcomes in patients with TAVR. The Core Valve High-Risk Pivotal Trial confirmed that the 1-year rate of all-cause mortality and acute kidney injury was significantly greater in patients with severe prosthesis-patient mismatch compared with nonsevere prosthesis-patient mismatch (20.6% versus 12.0% [P=0.0145] for death and 19.2% versus 8.5% [P=0.0008] for acute kidney injury). 17 In the PARTNER trial, prosthesis-patient mismatch was an independent predictor of less left ventricular (LV) mass regression at 1 year, and in patients with no PVR, it predicted 1-year mortality. 18 It thus seems likely that with long-term follow-up, the outcomes for the Lotus Valve may begin to diverge.
Given the high post-TAVR gradients, the absence of LV mass regression over the REPRISE III 1-year follow-up period may be partially explained. However, the failure to show any LV mass regression after 1 year is somewhat surprising and counterintuitive given an expected reduction in pressure overload and the results of prior trials. In the PARTNER I trial, there was a 9.4±21.6% reduction in LV mass at 1 year (P<0.001 compared with baseline). 19 In the Core Valve trial, LV mass fell from a baseline of 132.32±36. Another important finding by Asch et al 15 was the gradual reduction in AVA and Doppler velocity index for both valves. This finding is in contradiction to the finding of the Core Valve pivotal trial, where Oh et al 20 reported a 1-year decrease in peak and mean transaortic gradients and a statistically significant 5% increase in AVA compared with baseline (from 1.78±0.51 cm to 1.87±0.54 cm 2 ). Given that 44% of patients showed a ≥1 grade improvement in PVR at 1 year, Oh et al 20 proposed that gradual remodeling (ie, expansion) of the self-expanding valve could be the explanation. The PARTNER study by Douglas et al 2 also showed numerically smaller (statistically no different) gradients immediately after TAVR compared with 5 years. Thus, although both the Core Valve and Lotus Valves supposedly show similar reductions in AVA compared with baseline, the current report is somewhat worrisome as we move into a lower risk patient population.
Clearly, the Lotus Valve was noninferior to the Core Valve for PVR after TAVR that helped drive the difference in composite primary end point for the medium and large valve sizes. Indeed, the 0.9% moderate or greater PVR rate is remarkable and a significant strength of this device. Nonetheless, the trial found no significant overall difference between the 2 devices in all-cause mortality or composite end points. This finding may be related to the tradeoff between lower PVR and higher gradients (with possible prosthesis-patient mismatch) along with higher PPM use.
As newer iterations of commercially available valves reduce the incidence of PVR while continuing to show lower gradients and PPM use, it is unclear whether the Lotus Valve, like the lotus flower, will rise above the muddy waters to float on the surface of the TAVR world. Long-term outcomes will help clarify the importance of the hemodynamic and procedural outcomes reported to date.
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